Table of Contents

company-logo

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Brainstorm Cell Therapeutics Dividend Announcement

• Brainstorm Cell Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Brainstorm Cell Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Brainstorm Cell Therapeutics Dividend History

Brainstorm Cell Therapeutics Dividend Yield

Brainstorm Cell Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Brainstorm Cell Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Brainstorm Cell Therapeutics Financial Ratios

P/E ratio-0.53
PEG ratio-0.01
P/B ratio-1.17
ROE279.58%
Payout ratio0.00%
Current ratio0.05
Quick ratio0.05
Cash Ratio0.02

Brainstorm Cell Therapeutics Dividend FAQ

Does Brainstorm Cell Therapeutics stock pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends to its shareholders.
Has Brainstorm Cell Therapeutics ever paid a dividend?
No, Brainstorm Cell Therapeutics has no a history of paying dividends to its shareholders. Brainstorm Cell Therapeutics is not known for its dividend payments.
Why doesn't Brainstorm Cell Therapeutics pay dividends?
There are several potential reasons why Brainstorm Cell Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Brainstorm Cell Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Brainstorm Cell Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Brainstorm Cell Therapeutics a dividend aristocrat?
Brainstorm Cell Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Brainstorm Cell Therapeutics a dividend king?
Brainstorm Cell Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Brainstorm Cell Therapeutics a dividend stock?
No, Brainstorm Cell Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Brainstorm Cell Therapeutics stocks?
To buy Brainstorm Cell Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Brainstorm Cell Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.